Covered recipient · General Payments record
TODD E SCHLESINGER
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$447,412.48
443 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $291,558.00 | 68 |
| Consulting Fee | $105,619.00 | 39 |
| Travel and Lodging | $40,300.97 | 154 |
| Food and Beverage | $9,852.64 | 180 |
| Education | $81.87 | 2 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $122,890.00 | 110 |
| UCB, Inc. | $50,304.86 | 73 |
| Janssen Biotech, Inc. | $47,598.88 | 31 |
| PFIZER INC. | $46,361.82 | 31 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $36,379.51 | 40 |
| E.R. Squibb & Sons, L.L.C. | $27,923.02 | 23 |
| Regeneron Pharmaceuticals, Inc. | $27,266.18 | 24 |
| Arcutis Biotherapeutics, Inc. | $26,287.57 | 28 |
| Galderma Laboratories, L.P. | $21,312.52 | 17 |
| Almirall LLC | $12,458.21 | 10 |
| Lilly USA, LLC | $10,019.42 | 6 |
| ABBVIE INC. | $9,921.01 | 12 |
| Janssen Global Services, LLC | $3,850.39 | 4 |
| Biofrontera Inc. | $3,063.82 | 5 |
| Verrica Pharmaceuticals Inc. | $678.25 | 5 |
| Novartis Pharmaceuticals Corporation | $239.80 | 6 |
| LEO Pharma Inc. | $238.98 | 4 |
| Celgene Corporation | $146.40 | 1 |
| Incyte Corporation | $135.61 | 4 |
| GENZYME CORPORATION | $107.79 | 2 |
| Janssen Research & Development, LLC | $102.57 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $60.46 | 1 |
| STRATA Skin Sciences, Inc. | $27.58 | 2 |
| Dermavant Sciences, Inc. | $24.31 | 1 |
| REVANCE THERAPEUTICS, INC. | $13.52 | 1 |
Page 2 of 9; records 51–100 of 443 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
TODD E SCHLESINGER
NPI 1538135280 · CMS profile ID 69562
Allopathic & Osteopathic Physicians / Dermatology
CHARLESTON, SC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 9; records 51–100 of 443 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1538135280?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- TODD E SCHLESINGER, NPI 1538135280, CMS profile ID 69562. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 9; records 51–100 of 443 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538135280?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). TODD E SCHLESINGER, NPI 1538135280, CMS profile ID 69562. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 9; records 51–100 of 443 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538135280?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- TODD E SCHLESINGER, NPI 1538135280, CMS profile ID 69562, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 9; records 51–100 of 443 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1538135280?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
443 matching records · $447,412.48 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 443.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $1,147.00 | 11/22/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114404721 | CMS |
| Regeneron Pharmaceuticals, Inc. | $1,147.00 | 11/22/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114404723 | CMS |
| Regeneron Pharmaceuticals, Inc. | $5,735.00 | 11/22/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114404725 | CMS |
| Regeneron Pharmaceuticals, Inc. | $1,147.00 | 11/22/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114404727 | CMS |
| Novartis Pharmaceuticals Corporation | $18.66 | 11/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087157853 | CMS |
| Incyte Corporation | $22.61 | 11/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141211591 | CMS |
| Lilly USA, LLC | $1,600.00 | 11/20/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155959220 | CMS |
| Galderma Laboratories, L.P. | $5,100.00 | 11/19/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145326696 | CMS |
| Regeneron Pharmaceuticals, Inc. | $134.32 | 11/19/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114404713 | CMS |
| Dermavant Sciences, Inc. | $24.31 | 11/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127929704 | CMS |
| Janssen Biotech, Inc. | $1,700.00 | 11/18/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078624720 | CMS |
| Regeneron Healthcare Solutions, Inc. | $7.23 | 11/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114161532 | CMS |
| Regeneron Pharmaceuticals, Inc. | $220.93 | 11/18/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114404711 | CMS |
| Regeneron Pharmaceuticals, Inc. | $124.23 | 11/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114404709 | CMS |
| Arcutis Biotherapeutics, Inc. | $89.98 | 11/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121077045 | CMS |
| UCB, Inc. | $36.06 | 11/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143080738 | CMS |
| Regeneron Healthcare Solutions, Inc. | $167.53 | 11/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114161514 | CMS |
| Regeneron Healthcare Solutions, Inc. | $70.71 | 11/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114161519 | CMS |
| Regeneron Healthcare Solutions, Inc. | $10.51 | 11/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114161523 | CMS |
| Regeneron Healthcare Solutions, Inc. | $36.77 | 11/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114161527 | CMS |
| Regeneron Pharmaceuticals, Inc. | $308.33 | 11/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114404707 | CMS |
| UCB, Inc. | $99.08 | 11/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143080736 | CMS |
| Arcutis Biotherapeutics, Inc. | $1,500.00 | 11/10/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121077047 | CMS |
| UCB, Inc. | $8.33 | 11/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143080706 | CMS |
| UCB, Inc. | $8.33 | 11/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143080708 | CMS |
| UCB, Inc. | $8.33 | 11/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143080710 | CMS |
| UCB, Inc. | $8.33 | 11/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143080712 | CMS |
| UCB, Inc. | $8.34 | 11/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143080714 | CMS |
| UCB, Inc. | $8.34 | 11/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143080716 | CMS |
| UCB, Inc. | $20.00 | 11/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143080718 | CMS |
| UCB, Inc. | $20.00 | 11/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143080720 | CMS |
| UCB, Inc. | $20.00 | 11/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143080722 | CMS |
| UCB, Inc. | $127.32 | 11/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143080724 | CMS |
| UCB, Inc. | $127.32 | 11/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143080726 | CMS |
| UCB, Inc. | $127.32 | 11/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143080728 | CMS |
| UCB, Inc. | $263.98 | 11/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143080730 | CMS |
| UCB, Inc. | $263.98 | 11/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143080732 | CMS |
| UCB, Inc. | $263.99 | 11/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143080734 | CMS |
| Lilly USA, LLC | $1,200.00 | 11/08/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155954106 | CMS |
| Lilly USA, LLC | $3,200.00 | 11/08/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155956682 | CMS |
| Regeneron Healthcare Solutions, Inc. | $155.22 | 11/08/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114161505 | CMS |
| Regeneron Healthcare Solutions, Inc. | $181.60 | 11/08/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114161510 | CMS |
| Almirall LLC | $1,600.00 | 11/07/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120640888 | CMS |
| Almirall LLC | $1,600.00 | 11/07/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120640892 | CMS |
| Regeneron Healthcare Solutions, Inc. | $217.31 | 11/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114161488 | CMS |
| Regeneron Healthcare Solutions, Inc. | $5.69 | 11/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114161492 | CMS |
| Regeneron Healthcare Solutions, Inc. | $137.18 | 11/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114161497 | CMS |
| Regeneron Healthcare Solutions, Inc. | $58.02 | 11/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114161501 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $30.83 | 11/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152209194 | CMS |
| Lilly USA, LLC | $19.42 | 11/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135450612 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,490.91 | 10 |
| PY2025 | Principal investigator | $218,592.72 | 37 |
| PY2024 | Principal investigator | $358,462.53 | 47 |
| PY2023 | Recipient | $522.02 | 2 |
| PY2023 | Principal investigator | $581,976.09 | 77 |
| PY2022 | Recipient | $20,050.00 | 4 |
| PY2022 | Principal investigator | $577,263.69 | 95 |
| PY2021 | Recipient | $1,947.39 | 2 |
| PY2021 | Principal investigator | $744,850.94 | 70 |
| PY2020 | Recipient | $1,879.72 | 4 |
| PY2020 | Principal investigator | $730,171.91 | 103 |
| PY2019 | Recipient | $6,840.75 | 4 |
| PY2019 | Principal investigator | $1,328,013.12 | 129 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
47 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Biofrontera Inc. | $9,570.50 | 12/22/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF THE CAROLINAS | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907797 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $247.51 | 12/11/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF THE CAROLINAS LLC | CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY | No dispute reported | 06/30/2026 | 1184270213 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,515.20 | 12/11/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF THE CAROLINAS | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184274464 |
| Principal investigator 1 | ABBVIE INC. | $2,858.10 | 12/04/2025 | Non-covered Recipient Entity CRCC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202526690 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,125.00 | 11/14/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF THE CAROLINAS | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184261321 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,418.40 | 11/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF THE CAROLINAS | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup | No dispute reported | 06/30/2026 | 1190307969 |
| Principal investigator 1 | ABBVIE INC. | $8,003.57 | 11/05/2025 | Non-covered Recipient Entity CRCC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202522915 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,150.00 | 10/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF THE CAROLINAS | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184250651 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,463.33 | 10/10/2025 | Non-covered Recipient Entity Vial Health | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435523 |
| Principal investigator 1 | ABBVIE INC. | $9,105.87 | 10/09/2025 | Non-covered Recipient Entity CRCC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202513859 |
| Principal investigator 1 | Biofrontera Inc. | $7,567.50 | 09/30/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF THE CAROLINAS | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS | No dispute reported | 06/30/2026 | 1208907624 |
| Principal investigator 1 | Biofrontera Inc. | $7,395.30 | 09/30/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF THE CAROLINAS | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF SUPERFICIALBASAL CELL CARCINOMA(SBCC) WITH PHOTODYNAMIC THERAPY (PDT). | No dispute reported | 06/30/2026 | 1208907629 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $11,000.00 | 09/30/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF THE CAROLINAS LLC | A Clinical Study to Assess Efficacy and Tolerability of a Topical Skincare Product on Adults With Mature, Crepey Skin | No dispute reported | 06/30/2026 | 1234516876 |
| Principal investigator 1 | ABBVIE INC. | $20,954.91 | 09/04/2025 | Non-covered Recipient Entity CRCC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202509590 |
| Principal investigator 1 | ABBVIE INC. | $3,746.55 | 08/06/2025 | Non-covered Recipient Entity CRCC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202502915 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $16,334.00 | 07/23/2025 | Non-covered Recipient Entity Clinical Research Center Of The Carolinas | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | No dispute reported | 06/30/2026 | 1235998028 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,206.47 | 07/17/2025 | Non-covered Recipient Entity Vial Health | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435519 |
| Principal investigator 1 | ABBVIE INC. | $1,705.80 | 07/02/2025 | Non-covered Recipient Entity CRCC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202495619 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $18.20 | 07/01/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184122235 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $42.00 | 07/01/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184122237 |
| Principal investigator 1 | Biofrontera Inc. | $9.86 | 06/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF THE CAROLINAS | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF SUPERFICIALBASAL CELL CARCINOMA(SBCC) WITH PHOTODYNAMIC THERAPY (PDT). | No dispute reported | 06/30/2026 | 1208907492 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,198.00 | 06/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF THE CAROLINAS | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184209159 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,342.00 | 06/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF THE CAROLINAS | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184209161 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $51.86 | 06/12/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184122221 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $57.46 | 06/12/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184122223 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $98.90 | 06/12/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184122225 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $103.02 | 06/12/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184122227 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $127.07 | 06/12/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184122229 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $351.03 | 06/12/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184122231 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $418.88 | 06/12/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184122233 |
| Principal investigator 1 | ABBVIE INC. | $2,040.75 | 06/03/2025 | Non-covered Recipient Entity CRCC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202489377 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $625.00 | 05/08/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF THE CAROLINAS LLC | CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY | No dispute reported | 06/30/2026 | 1184193687 |
| Principal investigator 1 | ABBVIE INC. | $5,095.80 | 05/07/2025 | Non-covered Recipient Entity CRCC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202483161 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $222.49 | 04/30/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184122219 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,103.24 | 04/14/2025 | Non-covered Recipient Entity Vial Health | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435515 |
| Principal investigator 1 | ABBVIE INC. | $1,429.05 | 04/03/2025 | Non-covered Recipient Entity CRCC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202470865 |
| Principal investigator 1 | ABBVIE INC. | $2,943.96 | 03/07/2025 | Non-covered Recipient Entity CRCC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202460463 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,600.00 | 03/04/2025 | Non-covered Recipient Entity Clinical Research Center Of The Carolinas | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226089575 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,558.00 | 02/21/2025 | Non-covered Recipient Entity CRCC LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223275475 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 02/21/2025 | Non-covered Recipient Entity CRCC LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223275477 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $500.00 | 02/21/2025 | Non-covered Recipient Entity CRCC LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223275479 |
| Principal investigator 1 | Biofrontera Inc. | $14,541.50 | 02/14/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF THE CAROLINAS | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907296 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,206.47 | 02/07/2025 | Non-covered Recipient Entity Vial Health | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435511 |
| Principal investigator 1 | ABBVIE INC. | $4,578.81 | 02/06/2025 | Non-covered Recipient Entity CRCC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202447305 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $34,689.62 | 02/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF THE CAROLINAS | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup | No dispute reported | 06/30/2026 | 1190307971 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $7,962.65 | 01/17/2025 | Non-covered Recipient Entity Clinical Research Center Of The Carolinas | Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) | No dispute reported | 06/30/2026 | 1235998030 |
| Principal investigator 1 | Biofrontera Inc. | $2,800.00 | 01/15/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF THE CAROLINAS | A NON-RANODMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF BF-200 ALA (AMELUZ) AND BF-RHODOLED XL IN THE EXPANDED FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS ON THE FACE AND SCALP WITH PHOTODYNAMIC THERAPY (PDT) | No dispute reported | 06/30/2026 | 1208907261 |